Enhancement of Chemotherapy Agents

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 1982 Mar 1

PMID 7107378

Citations 33

Authors

N J McNally

Affiliations

Soon will be listed here.

Abstract

The interaction in vivo between misonidazole and cytotoxic drugs is reviewed. In general MISO interacts best with bifunctional alkylating agents and nitrosoureas when there is generally a therapeutic gain at large MISO doses. The interaction is unlikely to be a result of pharmacokinetic effects of MISO, but may reflect its ability to inhibit recovery from drug induced damage. It is important to extend these studies to clinically relevant MISO doses simulating human pharmacokinetics.

Citing Articles

Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.

Rustamzadeh E, Li C, Doumbia S, Hall W, Vallera D J Neurooncol. 2003; 65(1):63-75.

PMID: 14649886 DOI: 10.1023/a:1026238331739.

Immunotoxin therapy for CNS tumor.

Rustamzadeh E, Low W, Vallera D, Hall W J Neurooncol. 2003; 64(1-2):101-16.

PMID: 12952291 DOI: 10.1007/BF02700025.

The experimental development of bioreductive drugs and their role in cancer therapy.

Workman P, Stratford I Cancer Metastasis Rev. 1993; 12(2):73-82.

PMID: 8375022 DOI: 10.1007/BF00689802.

Hypoxia and drug resistance.

Teicher B Cancer Metastasis Rev. 1994; 13(2):139-68.

PMID: 7923547 DOI: 10.1007/BF00689633.

Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Brooks S, Korbut T, Dupuis N, Holden S, Teicher B Cancer Chemother Pharmacol. 1995; 36(5):431-8.

PMID: 7634385 DOI: 10.1007/BF00686193.